Prescription RequiredREGORAFENIB 40 mg (Resihance) is a prescription targeted anticancer medicine used to treat certain advanced cancers, including metastatic colorectal cancer (mCRC), gastrointestinal stromal tumours (GIST), and hepatocellular carcinoma (HCC) after other treatments have not been effective. It belongs to a class of medicines called multikinase inhibitors and helps slow cancer growth by blocking proteins involved in tumour development and the formation of new blood vessels.
| Generic name | REGORAFENIB |
| Strength | 40 mg |
| Manufacturer | Zydus |
| Package size | 28 Tablets |
| Used for | Metastatic colorectal cancer (mCRC), gastrointestinal stromal tumours (GIST), and hepatocellular carcinoma (HCC) |
| Availability | In Stock |
| Shipping to | USA, UK, Australia, Canada, New Zealand, Philippines, Tunisia, France, Italy, South Korea, Albania, Romania, Hong Kong, Malaysia, Thailand, Singapore, UAE, Georgia, Armenia, Saudi Arabia, Qatar, Kuwait, South Africa, and many other countries. |
Regorafenib 40 mg works by blocking multiple protein kinases involved in cancer-cell growth, tumour blood vessel formation, and cancer spread. By inhibiting these signalling pathways, it helps slow the growth of cancer cells and limits the blood supply needed by tumours.
Dr. Neeru Mehta holds a Doctor of Medicine (MD) degree and has a professional interest in oncology and cancer care. Her interests include cancer treatments, monitoring treatment progress, managing side effects and supportive care.
